T cell immunotherapy makes a big difference in the fight against cancer by activating the patient’s immune system and priming the patient’s own T cells to recognize, attack and destroy cancer cells. However, not all patients respond to this treatment, so a better understanding of the properties of engineered T cells is needed to improve clinical responses.
The study, published in the journal Nature Cancer and led by professor Naveen Varadarajan of the University of Texas MD Anderson, uses the TIMING method, which uses artificial intelligence to evaluate cell behavior, movement and killing ability.
The scientists also found that the CD8-fit signature was present on prefabricated T cells, persisted after administration in patients, and most importantly, was associated with long-term positive clinical responses.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
